TGF-β signaling in cancer metastasis
The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Abstract
The transforming growth factor (TGF)-β signaling events are well known to control diverse processes and numerous responses, such as cell proliferation, differentiation, apoptosis, and migration. TGF-β signaling plays context-dependent roles in cancer: in pre-malignant cells TGF-β primarily functions as a tumor suppressor, while in the later stages of cancer TGF-β signaling promotes invasion and metastasis. Recent studies have also suggested that the cross-talk between TGF-β signaling and other signaling pathways, such as Hippo, Wnt, EGFR/RAS, and PI3K/AKT pathways, may substantially contribute to our current understanding of TGF-β signaling and cancer. As a result of the wide-ranging effects of TGF-β, blockade of TGF-β and its downstream signaling components provides multiple therapeutic opportunities. Therefore, the outlook for anti-TGF-β signaling therapy for numerous diseases appears bright and will provide valuable information and thinking on the drug molecular design. In this review, we focus on recent insights into the regulation of TGF-β signaling in cancer metastasis which may contribute to the development of novel cancer-targeting therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, cancer cells adapt to the protective TGF‐β signaling and utilize its moonlighting functions to create a conducive TME by activating CAFs, promoting angiogenesis and ECM production, and suppressing anti‐tumor immune responses [160, 161, 162].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [162]
Citations
Cites
A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?
Salmena, L., Poliseno, L., Tay, Y., Kats, L., & Pandolfi, P. P. (2011) · Cell · doi:10.1016/j.cell.2011.07.014 · Cited by 7,262
Long non-coding RNAs: insights into functions
Mercer, T. R., Dinger, M. E., & Mattick, J. S. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2521 · Cited by 5,654 · cited 1×
“LncRNAs can regulate many important cancer-associated phenotypes, including proliferation, apoptosis, or cell migration, through their interactions with DNA, chromatin, signaling and regulatory proteins, and a variety of cellular RNA species [74,75].”
BackgroundSmad-dependent and Smad-independent pathways in TGF-β family signalling
Derynck, R., & Zhang, Y. E. (2003) · Nature · doi:10.1038/nature02006 · Cited by 5,373
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis
Gupta, R. A., Shah, N., Wang, K. C., Kim, J., Horlings, H. M., Wong, D. J., Tsai, M.-C., Hung, T., Argani, P., Rinn, J. L., et al. (2010) · Nature · doi:10.1038/nature08975 · Cited by 5,218 · cited 1×
“The HOX-associated lncRNA HOTAIR can reprogram the chromatin landscape genomewide via recruitment of polycomb repressive complex 2 (PRC2), leading to increased breast cancer invasiveness and metastasis [87].”
BackgroundTumour exosome integrins determine organotropic metastasis
Hoshino, A., Costa-Silva, B., Shen, T.-L., Rodrigues, G., Hashimoto, A., Tesic Mark, M., Molina, H., Kohsaka, S., Di Giannatale, A., Ceder, S., et al. (2015) · Nature · doi:10.1038/nature15756 · Cited by 5,101 · cited 1×
“Certain tumors produce metastasis to specific organs independent of vascular anatomy, rate of blood flow, and the number of tumor cells delivered to each organ, and this organotropic metastasis depends on the extracellular vesicles such as exosomal integrins α6β4 and α6β1 [62].”
BackgroundEvolution and Functions of Long Noncoding RNAs
Ponting, C. P., Oliver, P. L., & Reik, W. (2009) · Cell · doi:10.1016/j.cell.2009.02.006 · Cited by 4,208 · cited 1×
“LncRNAs can regulate many important cancer-associated phenotypes, including proliferation, apoptosis, or cell migration, through their interactions with DNA, chromatin, signaling and regulatory proteins, and a variety of cellular RNA species [74,75].”
BackgroundTumor Metastasis: Molecular Insights and Evolving Paradigms
Valastyan, S., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.09.024 · Cited by 4,011
Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., Vadas, M. A., Khew-Goodall, Y., & Goodall, G. J. (2008) · Nature Cell Biology · doi:10.1038/ncb1722 · Cited by 3,863 · cited 1×
“The miR-200 family has been identified to repress EMT and tumor invasion by targeting the 3′ UTRs of the zinc-finger E-box binding factors 1 and 2 (ZEB1/2) [84,85].”
BackgroundMassagué, J. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3434 · Cited by 3,128
Long non-coding RNAs: new players in cell differentiation and development
Fatica, A., & Bozzoni, I. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3606 · Cited by 2,980 · cited 1×
“LncRNA BRAF (V600E) regulates melanoma cell migration and lncRNA GAPLINC regulates CD44dependent cell invasiveness [78,79].”
BackgroundTGF-β-induced epithelial to mesenchymal transition
Xu, J., Lamouille, S., & Derynck, R. (2009) · Cell Research · doi:10.1038/cr.2009.5 · Cited by 2,804
The emerging role of lncRNAs in cancer
Huarte, M. (2015) · Nature Medicine · doi:10.1038/nm.3981 · Cited by 2,702 · cited 1×
“LncRNA BRAF (V600E) regulates melanoma cell migration and lncRNA GAPLINC regulates CD44dependent cell invasiveness [78,79].”
BackgroundA multigenic program mediating breast cancer metastasis to bone
Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Kakonen, S. M., Cordón-Cardo, C., Guise, T. A., & Massagué, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00132-6 · Cited by 2,597
A Long Noncoding RNA Controls Muscle Differentiation by Functioning as a Competing Endogenous RNA
Cesana, M., Cacchiarelli, D., Legnini, I., Santini, T., Sthandier, O., Chinappi, M., Tramontano, A., & Bozzoni, I. (2011) · Cell · doi:10.1016/j.cell.2011.09.028 · Cited by 2,554
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
Yu, M., Bardia, A., Wittner, B. S., Stott, S. L., Smas, M. E., Ting, D. T., Isakoff, S. J., Ciciliano, J. C., Wells, M. N., Shah, A. M., et al. (2013) · Science · doi:10.1126/science.1228522 · Cited by 2,476
Mechanism of activation of the TGF-β receptor
Wrana, J. L., Attisano, L., Wieser, R., Ventura, F., & Massagué, J. (1994) · Nature · doi:10.1038/370341a0 · Cited by 2,337
The Future of Peptide‐based Drugs
Craik, D. J., Fairlie, D. P., Liras, S., & Price, D. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12055 · Cited by 1,979
A genomic and functional inventory of deubiquitinating enzymes.
Nijman, S. M. B., Luna-Vargas, M. P. A., Velds, A., Brummelkamp, T. R., Dirac, A. M. G., Sixma, T. K., & Bernards, R. (2005) · Cell · doi:10.1016/j.cell.2005.11.007 · Cited by 1,854 · cited 1×
“The conjugating function of E3 ligases is opposed by deubiquitylating enzymes (DUBs) [29].”
BackgroundBurk, U., Schubert, J., Wellner, U., Schmalhofer, O., Vincan, E., Spaderna, S., & Brabletz, T. (2008) · EMBO reports · doi:10.1038/embor.2008.74 · Cited by 1,722 · cited 1×
“The miR-200 family has been identified to repress EMT and tumor invasion by targeting the 3′ UTRs of the zinc-finger E-box binding factors 1 and 2 (ZEB1/2) [84,85].”
BackgroundThe EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs
Wellner, U., Schubert, J., Burk, U. C., Schmalhofer, O., Zhu, F., Sonntag, A., Waldvogel, B., Vannier, C., Darling, D., Hausen, A. Z., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1998 · Cited by 1,699
Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer
Siegel, P. M., & Massagué, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1208 · Cited by 1,604
Yuan, J.-H., Yang, F., Wang, F., Ma, J.-Z., Guo, Y.-J., Tao, Q.-F., Liu, F., Pan, W., Wang, T.-T., Zhou, C.-C., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.010 · Cited by 1,515 · cited 2×
“[80] reported that lncRNA-ATB is activated by TGF-β in hepatocellular carcinoma (HCC) cells and promotes epithelial to mesenchymal transition, cellular invasion, and organ colonization by HCC cells via two distinct RNA–RNA interactions (Fig.”
BackgroundTargeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466 · cited 1×
“Targeting of PI3K/AKT pathway for the treatment of cancer patients holds significant therapeutic promise [61].”
Identification of a Member of the MAPKKK Family as a Potential Mediator of TGF-β Signal Transduction
Yamaguchi, K., Shirakabe, K., Shibuya, H., Irie, K., Oishi, I., Ueno, N., Taniguchi, T., Nishida, E., & Matsumoto, K. (1995) · Science · doi:10.1126/science.270.5244.2008 · Cited by 1,343 · cited 1×
“JNK and p38 MAPK pathway activation by TGF-β is induced via TAK1, a MAPK kinase kinase (MAPKKK) family member [38].”
BackgroundTRAF6 is a signal transducer for interleukin-1
Cao, Z., Xiong, J., Takeuchi, M., Kurama, T., & Goeddel, D. V. (1996) · Nature · doi:10.1038/383443a0 · Cited by 1,303
Smad7 Binds to Smurf2 to Form an E3 Ubiquitin Ligase that Targets the TGFβ Receptor for Degradation
Kavsak, P., Rasmussen, R. K., Causing, C. G., Bonni, S., Zhu, H., Thomsen, G. H., & Wrana, J. L. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00134-9 · Cited by 1,205 · cited 2×
“USP4 and USP15 were found to activate the Type I receptors by counteracting receptor-ubiquitinating complexes through different mechanisms: USP15 influences TβRI-signaling indirectly, by acting on the SMAD7–SMURF2 complex, whereas USP4 acts directly on TβRI.”
BackgroundTGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4
Nakao, A. (1997) · The EMBO Journal · doi:10.1093/emboj/16.17.5353 · Cited by 1,070
Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs
Tay, Y., Kats, L., Salmena, L., Weiss, D., Tan, S. M., Ala, U., Karreth, F., Poliseno, L., Provero, P., Di Cunto, F., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.029 · Cited by 1,019
Bhowmick, N. A., Ghiassi, M., Bakin, A., Aakre, M., Lundquist, C. A., Engel, M. E., Arteaga, C. L., & Moses, H. L. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.1.27 · Cited by 1,004 · cited 1×
“TGF-β also activates GTPase RhoA and its downstream target p160 (ROCK), inducing actin stress fiber formation and mesenchymal characteristics [48,49].”
BackgroundYin, J. J., Selander, K., Chirgwin, J. M., Dallas, M., Grubbs, B. G., Wieser, R., Massagué, J., Mundy, G. R., & Guise, T. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci3523 · Cited by 986
TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4
Padua, D., Zhang, X. H.-F., Wang, Q., Nadal, C., Gerald, W. L., Gomis, R. R., & Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.01.046 · Cited by 952
The roles of TGFβ in the tumour microenvironment
Pickup, M., Novitskiy, S., & Moses, H. L. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3603 · Cited by 917
Ebisawa, T., Fukuchi, M., Murakami, G., Chiba, T., Tanaka, K., Imamura, T., & Miyazono, K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100008200 · Cited by 844 · cited 2×
“USP4 and USP15 were found to activate the Type I receptors by counteracting receptor-ubiquitinating complexes through different mechanisms: USP15 influences TβRI-signaling indirectly, by acting on the SMAD7–SMURF2 complex, whereas USP4 acts directly on TβRI.”
BackgroundThe regulation of TGFβ signal transduction
Moustakas, A., & Heldin, C.-H. (2009) · Development · doi:10.1242/dev.030338 · Cited by 832
Moustakas, A., & Heldin, C. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00550.x · Cited by 804 · cited 1×
“In the later phases of cancer progression, TGF-β signaling can promote EMT by increasing the expression of mesenchymal markers, such as N-cadherin and vimentin, and reducing expression of epithelial markers, such as E-cadherin [7,8].”
BackgroundTGF-β signaling and epithelial–mesenchymal transition in cancer progression
Katsuno, Y., Lamouille, S., & Derynck, R. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835b6371 · Cited by 786 · cited 1×
“In many types of cells, TGF-β-induced growth inhibition is mediated through SMAD-dependent inhibition of the expression of the c-MYC oncogene, cyclin-dependent kinases (CDKs) and CDC25A [5,6].”
BackgroundNon-Smad Signaling Pathways of the TGF-β Family
Zhang, Y. E. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022129 · Cited by 697
Distinct EMT programs control normal mammary stem cells and tumour-initiating cells
Ye, X., Tam, W. L., Shibue, T., Kaygusuz, Y., Reinhardt, F., Ng Eaton, E., & Weinberg, R. A. (2015) · Nature · doi:10.1038/nature14897 · Cited by 694 · cited 1×
“Tumor cells can undergo partial EMT in which cells lose cell polarity and cell–cell contacts, become more motile, and/or acquire fibroblastlike properties [50,51].”
BackgroundPrensner, J. R., Iyer, M. K., Sahu, A., Asangani, I. A., Cao, Q., Patel, L., Vergara, I. A., Davicioni, E., Erho, N., Ghadessi, M., et al. (2013) · Nature Genetics · doi:10.1038/ng.2771 · Cited by 669 · cited 1×
“Mechanistically, SChLAP1 was found to promote prostate cancer invasion and metastasis by antagonizing the tumorsuppressive functions of the SWI/SNF complex [89].”
BackgroundMechanism of TGF-β signaling to growth arrest, apoptosis, and epithelial–mesenchymal transition
Heldin, C.-H., Landström, M., & Moustakas, A. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.01.021 · Cited by 634
TGF-β Tumor Suppression through a Lethal EMT
David, C. J., Huang, Y.-H., Chen, M., Su, J., Zou, Y., Bardeesy, N., Iacobuzio-Donahue, C. A., & Massagué, J. (2016) · Cell · doi:10.1016/j.cell.2016.01.009 · Cited by 593
TRAF6 Mediates Smad-Independent Activation of JNK and p38 by TGF-β
Yamashita, M., Fatyol, K., Jin, C., Wang, X., Liu, Z., & Zhang, Y. E. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.09.002 · Cited by 559
The type I TGF-β receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner
Sorrentino, A., Thakur, N., Grimsby, S., Marcusson, A., von Bulow, V., Schuster, N., Zhang, S., Heldin, C.-H., & Landström, M. (2008) · Nature Cell Biology · doi:10.1038/ncb1780 · Cited by 553 · cited 5×
“JNK and p38 MAPK pathway activation by TGF-β is induced via TAK1, a MAPK kinase kinase (MAPKKK) family member [38].”
BackgroundInfluentialMu, Y., Gudey, S. K., & Landström, M. (2012) · Cell and Tissue Research · doi:10.1007/s00441-011-1201-y · Cited by 545
Restriction of intestinal stem cell expansion and the regenerative response by YAP
Barry, E. R., Morikawa, T., Butler, B. L., Shrestha, K., de la Rosa, R., Yan, K. S., Fuchs, C. S., Magness, S. T., Smits, R., Ogino, S., et al. (2013) · Nature · doi:10.1038/nature11693 · Cited by 543 · cited 1×
“YAP1, which is downregulated in breast cancers, has been reported as a tumor suppressor in multiple types of cancer [55,56], whereas 14-3-3σ stabilizes tumor suppressor p53, a SMAD partner for transactivation of p21 [57], one of the key executors of TGF-β’s cytostatic function.”
BackgroundSIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions
Vandewalle, C. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki965 · Cited by 542
Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway
Kang, Y., He, W., Tulley, S., Gupta, G. P., Serganova, I., Chen, C.-R., Manova-Todorova, K., Blasberg, R., Gerald, W. L., & Massagué, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506517102 · Cited by 532
Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing
Leary, R. J., Kinde, I., Diehl, F., Schmidt, K., Clouser, C., Duncan, C., Antipova, A., Lee, C., McKernan, K., De La Vega, F. M., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000702 · Cited by 517
Regulation of EMT by TGFβ in cancer
Heldin, C.-H., Vanlandewijck, M., & Moustakas, A. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.02.037 · Cited by 505
Ishida, T., Mizushima, S.-I., Azuma, S., Kobayashi, N., Tojo, T., Suzuki, K., Aizawa, S., Watanabe, T., Mosialos, G., Kieff, E., et al. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.46.28745 · Cited by 472
lncRNA Directs Cooperative Epigenetic Regulation Downstream of Chemokine Signals
Xing, Z., Lin, A., Li, C., Liang, K., Wang, S., Liu, Y., Park, P. K., Qin, L., Wei, Y., Hawke, D. H., et al. (2014) · Cell · doi:10.1016/j.cell.2014.10.013 · Cited by 447
MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling
Huang, S., Hölzel, M., Knijnenburg, T., Schlicker, A., Roepman, P., McDermott, U., Garnett, M., Grernrum, W., Sun, C., Prahallad, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.10.035 · Cited by 430 · cited 1×
“A low dose of TβRII appears to be sufficient for cytostatic SMAD activation, while an increase in TβRII levels contributes to cancer and drug resistance [59].”
BackgroundEdlund, S., Landström, M., Heldin, C.-H., & Aspenström, P. (2002) · Molecular Biology of the Cell · doi:10.1091/mbc.01-08-0398 · Cited by 418
Eichhorn, P. J. A., Rodón, L., Gonzàlez-Juncà, A., Dirac, A., Gili, M., Martínez-Sáez, E., Aura, C., Barba, I., Peg, V., Prat, A., et al. (2012) · Nature Medicine · doi:10.1038/nm.2619 · Cited by 409
Yang, Y.-A., Dukhanina, O. I., Tang, B., Mamura, M., Letterio, J. J., MacGregor, J., Patel, S. C., Khozin, S., Liu, Z.-Y., Green, J. D., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15333 · Cited by 404
Yang, Y.-A., Dukhanina, O., Tang, B., Mamura, M., Letterio, J. J., MacGregor, J., Patel, S. C., Khozin, S., Liu, Z.-Y., Green, J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215333 · Cited by 404
Ji, H., Greening, D. W., Barnes, T. W., Lim, J. W., Tauro, B. J., Rai, A., Xu, R., Adda, C., Mathivanan, S., Zhao, W., et al. (2013) · PROTEOMICS · doi:10.1002/pmic.201200562 · Cited by 357
Orphan nuclear receptor NR4A1 regulates transforming growth factor-β signaling and fibrosis
Palumbo-Zerr, K., Zerr, P., Distler, A., Fliehr, J., Mancuso, R., Huang, J., Mielenz, D., Tomcik, M., Fürnrohr, B. G., Scholtysek, C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3777 · Cited by 342 · cited 1×
“Intriguingly, TGF-β can also induce phosphorylation of tyrosine residues on TβRI and TβRII, thereby recruiting Grb2 and SOS which activate Ras and the Raf–MEK–Erk MAPK cascade [47].”
BackgroundUSP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type I receptor
Zhang, L., Zhou, F., Drabsch, Y., Gao, R., Snaar-Jagalska, B. E., Mickanin, C., Huang, H., Sheppard, K.-A., Porter, J. A., Lu, C. X., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2522 · Cited by 324 · cited 2×
“USP4 was identified as an important mediator of the cross-talk between the TGF-β and AKT signaling pathways [31] and activated AKT cooperates with TGF-β to antagonize the inhibitory effect of FAS-associated factor 1 (FAF1) on TGF-β signaling [33].”
BackgroundSelf-citationTransforming Growth Factor-β Receptors and Smads: Regulatory Complexity and Functional Versatility
Budi, E. H., Duan, D., & Derynck, R. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.04.005 · Cited by 289
Hu, Y., Wang, J., Qian, J., Kong, X., Tang, J., Wang, Y., Chen, H., Hong, J., Zou, W., Chen, Y., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0686 · Cited by 282
Regulation of Smurf2 Ubiquitin Ligase Activity by Anchoring the E2 to the HECT Domain
Ogunjimi, A. A., Briant, D. J., Pece-Barbara, N., Le Roy, C., Di Guglielmo, G. M., Kavsak, P., Rasmussen, R. K., Seet, B. T., Sicheri, F., & Wrana, J. L. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.028 · Cited by 280 · cited 1×
“In the receptor–SMAD7– SMURF1/2 complex, SMAD7 recruits the ubiquitin-conjugating E2 enzyme UbcH7 to stimulate the activity of SMURF1/2 [19].”
BackgroundFlockhart, R. J., Webster, D. E., Qu, K., Mascarenhas, N., Kovalski, J., Kretz, M., & Khavari, P. A. (2012) · Genome Research · doi:10.1101/gr.140061.112 · Cited by 277
MicroRNA control of epithelial–mesenchymal transition and metastasis
Zhang, J., & Ma, L. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9368-6 · Cited by 273 · cited 1×
“In addition to lncRNAs, miRNAs also play critical roles in regulation of TGF-β signaling, EMT, and cancer metastasis [90,91].”
BackgroundPrensner, J. R., Zhao, S., Erho, N., Schipper, M., Iyer, M. K., Dhanasekaran, S. M., Magi-Galluzzi, C., Mehra, R., Sahu, A., Siddiqui, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71113-1 · Cited by 264 · cited 1×
“overexpressed gene, associated with poor prognosis and metastatic progression [88].”
BackgroundCell-penetrating peptides transport therapeutics into cells
Ramsey, J. D., & Flynn, N. H. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.07.003 · Cited by 256
TRAF4 Promotes TGF-β Receptor Signaling and Drives Breast Cancer Metastasis
Zhang, L., Zhou, F., García de Vinuesa, A., de Kruijf, E. M., Mesker, W. E., Hui, L., Drabsch, Y., Li, Y., Bauer, A., Rousseau, A., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.07.014 · Cited by 229
Self-citationRNF12 Is an X-Encoded Dose-Dependent Activator of X Chromosome Inactivation
Jonkers, I., Barakat, T. S., Achame, E. M., Monkhorst, K., Kenter, A., Rentmeester, E., Grosveld, F., Grootegoed, J. A., & Gribnau, J. (2009) · Cell · doi:10.1016/j.cell.2009.10.034 · Cited by 229 · cited 1×
“Recent studies have shown that mouse RNF12 is an X-encoded, dose-dependent inducer of X chromosome inactivation (XCI) in mouse embryonic stem cells (ESCs) [23,24].”
BackgroundType I Transforming Growth Factor β Receptor Binds to and Activates Phosphatidylinositol 3-Kinase
Yi, J. Y., Shin, I., & Arteaga, C. L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413223200 · Cited by 228 · cited 10×
“Recent studies have also suggested that the cross-talk between TGF-β signaling and other signaling pathways, such as Hippo, Wnt, EGFR/RAS, and PI3K/AKT pathways, may substantially contribute to our current understanding of TGF-β signaling and cancer.”
BackgroundInfluentialEvaluation of Anti-TGF-β2 Antibody as a New Postoperative Anti-scarring Agent in Glaucoma Surgery
Mead, A. L., Wong, T. T. L., Cordeiro, M. F., Anderson, I. K., & Khaw, P. T. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-0978 · Cited by 225
Hamidi, A., Song, J., Thakur, N., Itoh, S., Marcusson, A., Bergh, A., Heldin, C.-H., & Landström, M. (2017) · Science Signaling · doi:10.1126/scisignal.aal4186 · Cited by 223
TGF-β-RI Kinase Inhibitor SD-208 Reduces the Development and Progression of Melanoma Bone Metastases
Mohammad, K. S., Javelaud, D., Fournier, P. G. J., Niewolna, M., McKenna, C. R., Peng, X. H., Duong, V., Dunn, L. K., Mauviel, A., & Guise, T. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2651 · Cited by 221
Crosstalk between TGF-β signaling and the microRNA machinery
Butz, H., Rácz, K., Hunyady, L., & Patócs, A. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.04.003 · Cited by 215
Arkadia amplifies TGF- superfamily signalling through degradation of Smad7
Koinuma, D. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg632 · Cited by 215
The TGF-β Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone
Fournier, P. G. J., Juárez, P., Jiang, G., Clines, G. A., Niewolna, M., Kim, H. S., Walton, H. W., Peng, X. H., Liu, Y., Mohammad, K. S., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.009 · Cited by 212
Komuro, A., Imamura, T., Saitoh, M., Yoshida, Y., Yamori, T., Miyazono, K., & Miyazawa, K. (2004) · Oncogene · doi:10.1038/sj.onc.1207885 · Cited by 205
Johnson, R. W., Nguyen, M. P., Padalecki, S. S., Grubbs, B. G., Merkel, A. R., Oyajobi, B. O., Matrisian, L. M., Mundy, G. R., & Sterling, J. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2993 · Cited by 197 · cited 1×
“GLI2 is a SMAD partner in TGF-β-induced parathyroid hormone-related protein (PTHrP) expression, a previously identified key determinant of TGF-β-induced bone metastasis [58].”
BackgroundLu, J., Guo, H., Treekitkarnmongkol, W., Li, P., Zhang, J., Shi, B., Ling, C., Zhou, X., Chen, T., Chiao, P. J., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.08.010 · Cited by 193 · cited 1×
“[53] demonstrated that 14-3-3ζ can potentiate TGF-β signaling during EMT and breast tumor progression.”
BackgroundHuman anti-transforming growth factor-beta2 antibody: a new glaucoma anti-scarring agent.
Cordeiro, M. F., GAY, J. A., & Khaw, P. T. (1999) · PubMed · Cited by 192
USP15 is a deubiquitylating enzyme for receptor-activated SMADs
Inui, M., Manfrin, A., Mamidi, A., Martello, G., Morsut, L., Soligo, S., Enzo, E., Moro, S., Polo, S., Dupont, S., et al. (2011) · Nature Cell Biology · doi:10.1038/ncb2346 · Cited by 190 · cited 2×
“USP15 has also been shown to act as a DUB of monoubiquitylated R-SMADs, thereby counteracting the inhibition of DNA binding [30].”
BackgroundBandyopadhyay, A., Agyin, J. K., Wang, L., Tang, Y., Lei, X., Story, B. M., Cornell, J. E., Pollock, B. H., Mundy, G. R., & Sun, L.-Z. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3565 · Cited by 185
Regulating the stability of TGFβ receptors and Smads
Lönn, P., Morén, A., Raja, E., Dahl, M., & Moustakas, A. (2009) · Cell Research · doi:10.1038/cr.2008.308 · Cited by 183
TRAF6 ubiquitinates TGFβ type I receptor to promote its cleavage and nuclear translocation in cancer
Mu, Y., Sundar, R., Thakur, N., Ekman, M., Gudey, S. K., Yakymovych, M., Hermansson, A., Dimitriou, H., Bengoechea-Alonso, M. T., Ericsson, J., et al. (2011) · Nature Communications · doi:10.1038/ncomms1332 · Cited by 182 · cited 1×
“Recent studies have revealed that TGF-β, via TRAF6, also can induce Lys63-linked polyubiquitination of TβRI, which promotes cleavage of TβRI by TNF-α converting enzyme (TACE) in a PKCζ-dependent manner [45].”
BackgroundNuclear receptor NR4A1 promotes breast cancer invasion and metastasis by activating TGF-β signalling
Zhou, F., Drabsch, Y., Dekker, T. J. A., de Vinuesa, A. G., Li, Y., Hawinkels, L. J. A. C., Sheppard, K.-A., Goumans, M.-J., Luwor, R. B., de Vries, C. J., et al. (2014) · Nature Communications · doi:10.1038/ncomms4388 · Cited by 180 · cited 1×
“NR4A1 was found to facilitate AXIN2–RNF12/ARKADIA-induced SMAD7 degradation [27].”
BackgroundSelf-citationEhata, S., Hanyu, A., Fujime, M., Katsuno, Y., Fukunaga, E., Goto, K., Ishikawa, Y., Nomura, K., Yokoo, H., Shimizu, T., et al. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2006.00357.x · Cited by 180
Xu, J., Acharya, S., Sahin, O., Zhang, Q., Saito, Y., Yao, J., Wang, H., Li, P., Zhang, L., Lowery, F. J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.025 · Cited by 179 · cited 2×
“1D11 has been shown to reduce the expression of both Gli2 and PTHrP and to significantly inhibit bone tumor metastases induced by NMuMG cells [52].”
BackgroundSelf-citationMaternal Rnf12/RLIM is required for imprinted X-chromosome inactivation in mice
Shin, J., Bossenz, M., Chung, Y., Ma, H., Byron, M., Taniguchi-Ishigaki, N., Zhu, X., Jiao, B., Hall, L. L., Green, M. R., et al. (2010) · Nature · doi:10.1038/nature09457 · Cited by 166 · cited 1×
“Recent studies have shown that mouse RNF12 is an X-encoded, dose-dependent inducer of X chromosome inactivation (XCI) in mouse embryonic stem cells (ESCs) [23,24].”
BackgroundCanonical Wnt suppressor, Axin2, promotes colon carcinoma oncogenic activity
Wu, Z.-Q., Brabletz, T., Fearon, E., Willis, A. L., Hu, C. Y., Li, X.-Y., & Weiss, S. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203015109 · Cited by 160 · cited 1×
“However, another group has reported NR4A1 as an endogenous inhibitor of TGF-β signaling by recruiting a repressor complex comprising SP1, SIN3A, CoREST, LSD1, and HDAC1 to TGF-β target genes, thereby limiting pro-fibrotic effects of TGF-β [28].”
BackgroundWatanabe, Y., Itoh, S., Goto, T., Ohnishi, E., Inamitsu, M., Itoh, F., Satoh, K., Wiercinska, E., Yang, W., Shi, L., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2009.10.028 · Cited by 160 · cited 1×
“High level of PMEPA1 in turn regulates negative feedback loops in TGF-β signaling [70].”
BackgroundJohansson, J., Berg, T., Kurzejamska, E., Pang, M.-F., Tabor, V, Jansson, M., Roswall, P., Pietras, K., Sund, M., Religa, P., et al. (2013) · Oncogene · doi:10.1038/onc.2013.322 · Cited by 153
Transforming Growth Factor β: Tumor Suppressor or Promoter? Are Host Immune Cells the Answer?
Yang, L., & Moses, H. L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2556 · Cited by 151 · cited 1×
“Each family member plays crucial roles in many cellular processes, including immune-suppression, growth inhibition, epithelial–mesenchymal transition (EMT), cell migration, invasion, and extracellular matrix (ECM) remodeling [2,3].”
BackgroundTGF-β Targets the Hippo Pathway Scaffold RASSF1A to Facilitate YAP/SMAD2 Nuclear Translocation
Pefani, D., Paňková, D., Abraham, A., Grawenda, A. M., Vlahov, N., Scrace, S., & Neill, E. O. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.05.012 · Cited by 149
Lacouture, M. E., Morris, J. C., Lawrence, D. P., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Berzofsky, J. A., Hsu, F. J., & Guitart, J. (2015) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-015-1653-0 · Cited by 145
Bach, I., Rodrı́guez-Esteban, C., Carrière, C., Bhushan, A., Krones, A., Rose, D. W., Glass, C. K., D, B. A. M., Belmonte, J. C. I., & Rosenfeld, M. G. (1999) · Nature Genetics · doi:10.1038/11970 · Cited by 140 · cited 1×
“RNF12 was originally identified as a protein that binds to the homeodomain protein LIM, and targets the LIM cofactor CLIM for degradation [22].”
BackgroundTransforming growth factor‐beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer
Schlingensiepen, K., Jaschinski, F., Lang, S. A., Moser, C., Geissler, E. K., Schlitt, H. J., Kielmanowicz, M., & Schneider, A. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01917.x · Cited by 139
Regulation of the p53-MDM2 pathway by 14-3-3 σ and other proteins
Lee, M., & Lozano, G. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.03.009 · Cited by 128
CCT6A suppresses SMAD2 and promotes prometastatic TGF-β signaling
Ying, Z., Tian, H., Li, Y., Lian, R., Li, W., Wu, S., Zhang, H., Wu, J., Liu, L., Song, J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90439 · Cited by 127
Yu, J., Lei, R., Zhuang, X., Li, X., Li, G., Lev, S., Segura, M. F., Zhang, X., & Hu, G. (2016) · Nature Communications · doi:10.1038/ncomms13884 · Cited by 126
miR-1269 promotes metastasis and forms a positive feedback loop with TGF-β
Bu, P., Wang, L., Chen, K.-Y., Rakhilin, N., Sun, J., Closa, A., Tung, K.-L., King, S., Kristine Varanko, A., Xu, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms7879 · Cited by 123
Single-molecule imaging reveals transforming growth factor-β-induced type II receptor dimerization
Zhang, W., Jiang, Y., Wang, Q., Ma, X., Xiao, Z., Zuo, W., Fang, X., & Chen, Y.-G. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908279106 · Cited by 122 · cited 1×
“have demonstrated that in the absence of TGF-β, TβRI and TβRII can be present on the cell surface as monomers rather than homodimers [10], while dimerization of both receptors occurs upon TGF-β stimulation [11].”
BackgroundBusch, S., Acar, A., Magnusson, Y., Gregersson, P., Rydén, L., & Landberg, G. (2015) · Oncogene · doi:10.1038/onc.2013.527 · Cited by 119 · cited 1×
“support cancer growth and survival [60].”
Inhibition of TGF-β signaling by 1D11 antibody treatment increases bone mass and quality in vivo
Edwards, J. R., Nyman, J. S., Lwin, S. T., Moore, M. M., Esparza, J., O'Quinn, E. C., Hart, A. J., Biswas, S., Patil, C. A., Lonning, S., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.139 · Cited by 109
SNX9 – a prelude to vesicle release
Lundmark, R., & Carlsson, S. R. (2009) · Journal of Cell Science · doi:10.1242/jcs.037135 · Cited by 104
Badour, K., McGavin, M. K. H., Zhang, J., Freeman, S., Vieira, C., Filipp, D., Julius, M., Mills, G. B., & Siminovitch, K. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610543104 · Cited by 103
Hu, H., Xu, Z., Li, C., Xu, C., Lei, Z., Zhang, H., & Zhao, J. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.04.017 · Cited by 96
Arkadia Enhances Nodal/TGF-β Signaling by Coupling Phospho-Smad2/3 Activity and Turnover
Mavrakis, K. J., Andrew, R. L., Lee, K. L., Petropoulou, C., Dixon, J. E., Navaratnam, N., Norris, D. P., & Episkopou, V. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050067 · Cited by 94
Zhang, L., Huang, H., Zhou, F., Schimmel, J., Gontan, C., Zhang, T., Barakat, T. S., Sheppard, K.-A., Mickanin, C., Porter, J. A., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.04.003 · Cited by 93 · cited 1×
“The E3 ubiquitin ligase RLIM/RNF12 has been identified as a key regulator of SMAD7 at the protein level [21].”
BackgroundSelf-citationZhao, B. M., & Hoffmann, F. M. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-10-0990 · Cited by 80
Yin, K., Yin, W., Wang, Y., Zhou, L., Liu, Y., Yang, G. S., Wang, J., & Lu, J. (2016) · Oncotarget · doi:10.18632/oncotarget.8233 · Cited by 78
AIP4 Restricts Transforming Growth Factor-β Signaling through a Ubiquitination-independent Mechanism
Lallemand, F., Seo, S. R., Ferrand, N., Pessah, M., L'Hoste, S., Rawadi, G., Roman-Roman, S., Camonis, J., & Atfi, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500188200 · Cited by 71 · cited 1×
“Interestingly, the E3 ubiquitin ligase AIP4 can also inhibit TGF-β signaling independent of ubiquitination via SMAD7 and TβRI [71].”
BackgroundRegulation of TGF-β Superfamily Signaling by SMAD Mono-Ubiquitination
Xie, F., Zhang, Z., Van Dam, H., Zhang, L., & Zhou, F. (2014) · Cells · doi:10.3390/cells3040981 · Cited by 70
Self-citationHu, Z., Gupta, J., Zhang, Z., Gerseny, H., Berg, A. S., Chen, Y., Zhang, Z., Du, H., Brendler, C. B., Xiao, X., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.040 · Cited by 67 · cited 1×
“A recent study showed that TGF-β supports the development of PCa bone metastases [64].”
BackgroundRegulation of EMT by KLF4 in Gastrointestinal Cancer
Cui, J., Shi, M., Quan, M., & Xie, K. (2013) · Current Cancer Drug Targets · doi:10.2174/15680096113136660104 · Cited by 65
Bai, N., Zhang, C., Liang, N., Zhang, Z., Chang, A., Yin, J., Li, Z., Li, N., Tan, X., Luo, N., et al. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.24345 · Cited by 63 · cited 1×
“YAP1, which is downregulated in breast cancers, has been reported as a tumor suppressor in multiple types of cancer [55,56], whereas 14-3-3σ stabilizes tumor suppressor p53, a SMAD partner for transactivation of p21 [57], one of the key executors of TGF-β’s cytostatic function.”
BackgroundNew concepts in breast cancer metastasis: tumor initiating cells and the microenvironment
Sleeman, J. P., & Cremers, N. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9122-6 · Cited by 60 · cited 1×
“However, the tumor microenvironment also plays an important role in metastasis [63].”
BackgroundZhang, W., Yuan, J., Yang, Y. P., Xu, L., Wang, Q., Zuo, W., Fang, X., & Chen, Y. (2010) · Cell Research · doi:10.1038/cr.2010.105 · Cited by 60 · cited 1×
“have demonstrated that in the absence of TGF-β, TβRI and TβRII can be present on the cell surface as monomers rather than homodimers [10], while dimerization of both receptors occurs upon TGF-β stimulation [11].”
BackgroundFAF1 phosphorylation by AKT accumulates TGF-β type II receptor and drives breast cancer metastasis
Xie, F., Jin, K., Shao, L., Fan, Y., Tu, Y., Li, Y., Yang, B., van Dam, H., ten Dijke, P., Weng, H., et al. (2017) · Nature Communications · doi:10.1038/ncomms15021 · Cited by 59 · cited 3×
“Recent studies also expand our understanding of the interplay between the TGF-β/SMAD and oncogenic activation of the PI3K/AKT pathway in cancer progression [33,118], which explains how TGF-β can be switched from a tumor suppressor to a tumor promoter.”
BackgroundSelf-citationKey role for ubiquitin protein modification in TGFβ signal transduction
De Boeck, M., & Ten Dijke, P. (2012) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2012.654858 · Cited by 47
A fully human antibody neutralising biologically active human TGFβ2 for use in therapy
Thompson, J. E., Vaughan, T. J., Williams, A. J., Wilton, J., Johnson, K. S., Bacon, L., Green, J. A., Field, R. P., Ruddock, S., MARTINS, M. S., et al. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(99)00060-5 · Cited by 44
FGFR1–WNT–TGF-β Signaling in Prostate Cancer Mouse Models Recapitulates Human Reactive Stroma
Carstens, J. L., Shahi, P., Van Tsang, S., Smith, B., Creighton, C. J., Zhang, Y., Seamans, A., Seethammagari, M., Vedula, I., Levitt, J. M., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1093 · Cited by 43 · cited 1×
“In PCa patients, the expression of PMEPA1 is increased by a high level of TGF-β in the primary tumor [69].”
BackgroundCell-penetrating peptides selectively targeting SMAD3 inhibit profibrotic TGF-β signaling
Kang, J. H., Jung, M.-Y., Yin, X., Andrianifahanana, M., Hernandez, D. M., & Leof, E. B. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88696 · Cited by 43
Methylation of thePMEPA1gene, a negative regulator of the androgen receptor in prostate cancer
Sharad, S., Ravindranath, L., Haffner, M. C., Li, H., Yan, W., Sesterhenn, I. A., Chen, Y., Ali, A., Srinivasan, A., McLeod, D. G., et al. (2014) · Epigenetics · doi:10.4161/epi.28710 · Cited by 31 · cited 1×
“However, compared with the primary tumor, expression of PMEPA1 was decreased in distant metastases of PCa patients due to accumulated methylation in the PMEPA1 promoter [72], suggesting that methylation of the PMEPA1 promoter may predict patient outcome, and that low methylation of the PMEPA1 is associated with bad pa…”
14-3-3ζ Orchestrates Mammary Tumor Onset and Progression via miR-221–Mediated Cell Proliferation
Rehman, S. K., Li, S.-H., Wyszomierski, S. L., Wang, Q., Li, P., Şahin, Ö., Xiao, Y. Q., Zhang, S., Xiong, Y., Yang, J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-2016 · Cited by 31 · cited 7×
“Recent studies have also suggested that the cross-talk between TGF-β signaling and other signaling pathways, such as Hippo, Wnt, EGFR/RAS, and PI3K/AKT pathways, may substantially contribute to our current understanding of TGF-β signaling and cancer.”
BackgroundInfluentialPtenRegulates Retinal Amacrine Cell Number by Modulating Akt, Tgfβ, and Erk Signaling
Tachibana, N., Cantrup, R., Dixit, R., Touahri, Y., Kaushik, G., Zinyk, D. L., Daftarian, N., Biernaskie, J. A., McFarlane, S., & Schuurmans, C. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0936-16.2016 · Cited by 31
Baumann, C., Lindholm, C. K., Rimoldi, D., & Lévy, F. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07698.x · Cited by 23
Wilkes, M. C., Repellin, C. E., Kang, J. H., Andrianifahanana, M., Yin, X., & Leof, E. B. (2015) · Molecular Biology of the Cell · doi:10.1091/mbc.e15-07-0545 · Cited by 14
Cited by
Targeting TGFβ signal transduction for cancer therapy
Liu, S., Ren, J., & ten Dijke, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00436-9 · Cited by 413
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
TGF-β signaling in the tumor metabolic microenvironment and targeted therapies
Shi, X., Yang, J., Deng, S., Xu, H., Wu, D., Zeng, Q., Wang, S., Hu, T., Wu, F., & Zhou, H. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01349-6 · Cited by 262
TGF‐β signaling: A recap of SMAD‐independent and SMAD‐dependent pathways
Aashaq, S., Batool, A., Mir, S. A., Beigh, M. A., Andrabi, K. I., & Shah, Z. A. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30529 · Cited by 211
The roles of exosomal miRNAs and lncRNAs in lung diseases
Li, Y., Yin, Z., Fan, J., Zhang, S., & Yang, W. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0080-7 · Cited by 190
Metadata
- Authors
- Xie, F., Ling, L., Van Dam, H., Zhou, F., & Zhang, L.
- Affiliations
- Soochow University (CN)
- Zhejiang University (CN)
- Venue
- Acta Biochimica et Biophysica Sinica
- Published
- 2018-01-01
- Volume
- 50
- Issue
- 1
- Pages
- 121-132
- ISSN
- 1672-9145 (ISSN-L)
- OpenAlex
- W2770010368
- Cited by
- 231
- References
- 125
- Citations by year
- 2026: 13 · 2025: 13 · 2024: 29 · 2023: 32 · 2022: 46 · 2021: 40 · 2020: 32 · 2019: 20 · 2018: 5
- FWCI
- 1.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Acta Biochimica et Biophysica Sinica (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Funders
- The National Basic Research Program of China (2016YFA0502500)
- National Natural Science Foundation of China (31471315, 31671457, 31571460, 31701232)
- The National Science Foundation for Post-doctoral Scientists of China (BX201700165)
- Zhejiang Natural Science Foundation (R14C070002)
- Jiangsu Natural Science Foundation (BK20150354)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- TGF-beta signaling, metastasis, tumor suppressor function, tumor invasion, signaling crosstalk, Hippo signaling pathway, Wnt signaling, PI3K/Akt signaling, anti-TGF-beta therapy
- MeSH terms
- Antineoplastic Agents, Humans, Models, Biological, Neoplasm Metastasis, Neoplasms, Signal Transduction, Transforming Growth Factor beta, Disease Progression, Tumor Suppressor Proteins, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.